What is the current price and volume for NOVN.SW stock?

NOVN.SW stock trades at **CHF129.60** intraday with volume at **3,670,447** shares. Day range is **CHF126.98–CHF129.60**, and relative volume is about **1.25** versus its 50-day average.

How does Meyka rate NOVN.SW stock and why?

Meyka AI rates NOVN.SW **78.14/100 (B+, BUY)**. The grade balances benchmark and sector comparisons, financial growth, key metrics, forecasts, and analyst signals. Grades are informational and not investment advice.

What near-term price target does Meyka give for NOVN.SW stock?

Meyka’s model lists a quarterly target of **CHF133.50**, implying a **+3.01%** move from **CHF129.60**. Models can diverge; treat targets as scenario guides, not guarantees.

What are the main risks for NOVN.SW stock investors?

Primary risks include patent expiries, regulatory setbacks, and execution costs for new manufacturing capacity. Valuation sensitivity is high given elevated price-to-book and price-to-sales ratios.

CH Stocks

CHF129.60 Novartis (NOVN.SW, SIX) intraday 26 Feb 2026: Meyka sees 18.35% upside

ByHuzaifa Zahoor February 26, 2026February 26, 2026

NOVN.SW stock trades at CHF129.60 intraday on the SIX exchange on 26 Feb 2026, with 3,670,447 shares traded and a high near CHF129.60. Volume is 1.25 times average, keeping Novartis among Switzerland’s most active names. Short-term momentum is strong, but valuation and near-term forecasts diverge, making active monitoring important.